NeuroBo Pharmaceuticals, Inc. (NRBO) Stock Analysis
DELISTED 2024
What happened to NeuroBo Pharmaceuticals, Inc. (NRBO) stock?
NeuroBo Pharmaceuticals, Inc. (NRBO) no longer trades on public markets. It was delisted in November 2024. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
NeuroBo Pharmaceuticals, Inc. (NRBO) trades at $2.36. NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative, infectious, and cardiometabolic diseases. Market cap: $20.3M, Sector: Healthcare.
Last analyzed: May 5, 2026Analyst Coverage for NRBO: NRBO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NRBO against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
NRBO: 1/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →NeuroBo Pharmaceuticals, Inc. (NRBO) Healthcare & Pipeline Overview
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology firm developing therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its pipeline features treatments like ANA001 for COVID-19 and NB-01 for diabetic neuropathy, positioning it within the competitive biotechnology landscape focused on unmet medical needs.
What Is the Investment Thesis for NRBO?
NeuroBo Pharmaceuticals presents a high-risk, high-reward investment opportunity typical of clinical-stage biotechnology companies. The primary value driver is the successful completion of clinical trials and subsequent regulatory approval of its drug candidates, particularly ANA001 for COVID-19 and NB-01 for diabetic neuropathy. Positive Phase 2/3 trial results for ANA001 could serve as a significant catalyst, potentially leading to increased investor interest and strategic partnerships. However, the company faces substantial risks, including clinical trial failures, regulatory hurdles, and the need for additional funding to support ongoing research and development. The company's small market capitalization of $20.3M reflects both the potential upside and the inherent uncertainties associated with its pipeline.
Based on FMP financials and quantitative analysis
NRBO Key Highlights
ANA001 is in Phase 2/3 clinical trials for treating patients with moderate COVID-19.
- NB-01 is being developed for the treatment of painful diabetic neuropathy.
- NB-02 targets the symptoms of cognitive impairment and the progression of neurodegenerative diseases.
- Gemcabene is being explored for an acute indication for COVID-19.
- The company's market capitalization is $0.02 billion.
Who Are NRBO's Competitors?
NRBO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NRBO's Key Strengths?
Pipeline of therapeutic programs targeting unmet medical needs.
- Focus on neurodegenerative, infectious, and cardiometabolic diseases.
- Clinical-stage development with potential for near-term catalysts.
- Experienced management team.
What Are NRBO's Weaknesses?
Limited financial resources.
- Small market capitalization.
- Reliance on successful clinical trial outcomes.
- Dependence on regulatory approvals.
What Could Drive NRBO Stock Higher?
Phase 2/3 clinical trial results for ANA001 in moderate COVID-19 patients.
- Progress updates on NB-01 clinical development for painful diabetic neuropathy.
- Potential strategic partnerships or collaborations to expand pipeline and funding.
- Continued research and development efforts to advance therapeutic programs.
What Are the Key Risks for NRBO?
Financial-distress signal — its Altman Z-Score of -14.51 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- Failure to achieve positive results in clinical trials.
- Regulatory setbacks or delays in obtaining approvals.
- Competition from other companies developing therapies for similar indications.
- Need for additional funding to support ongoing research and development.
- Negative beta of -0.28 indicates price moves inversely to the market.
What Are the Growth Opportunities for NRBO?
- Advancement of ANA001 for COVID-19: The successful completion of Phase 2/3 clinical trials for ANA001 and subsequent regulatory approval could provide a significant revenue stream. The global market for COVID-19 therapeutics remains substantial, driven by the ongoing need for effective treatments. Positive trial data could lead to partnerships with larger pharmaceutical companies for manufacturing and distribution, expanding market reach and accelerating commercialization.
- Development of NB-01 for Diabetic Neuropathy: NB-01 targets a large and growing market driven by the increasing prevalence of diabetes. Successful clinical trials and regulatory approval could position NB-01 as a valuable treatment option for painful diabetic neuropathy. The market for diabetic neuropathy treatments is projected to grow as the global diabetic population expands, offering a long-term growth opportunity for NeuroBo.
- Progress of NB-02 for Neurodegenerative Diseases: NB-02 addresses the symptoms of cognitive impairment and the progression of neurodegenerative diseases, a significant area of unmet medical need. The market for neurodegenerative disease therapies is substantial and growing, driven by the aging global population. Successful development of NB-02 could provide a valuable treatment option for conditions like Alzheimer's disease and other forms of dementia.
- Expansion of Pipeline through Strategic Partnerships: NeuroBo can expand its pipeline and diversify its risk by forming strategic partnerships with other biotechnology and pharmaceutical companies. Collaborations can provide access to new technologies, drug candidates, and funding, accelerating the development of innovative therapies. Strategic alliances can also enhance NeuroBo's credibility and visibility within the industry.
- Exploration of Gemcabene for COVID-19: While Gemcabene is being explored for an acute indication for COVID-19, further research and development could unlock additional therapeutic applications. The ongoing evolution of the COVID-19 virus and the emergence of new variants may create a sustained need for effective treatments. Further studies could identify specific patient populations or disease stages where Gemcabene offers a significant clinical benefit.
What Are NRBO's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Clinical trial data demonstrating efficacy and safety.
- Regulatory approval from agencies like the FDA.
- Expertise in developing therapies for neurodegenerative, infectious, and cardiometabolic diseases.
What Does NRBO Do?
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing therapies for neurodegenerative, infectious, and cardiometabolic diseases. The company's origins lie in addressing significant unmet medical needs through innovative drug development. Its pipeline includes several therapeutic programs, each targeting a specific disease area. ANA001, an oral niclosamide formulation, is currently in Phase 2/3 clinical trials for treating patients with moderate COVID-19. NB-01 is being developed for the treatment of painful diabetic neuropathy, a debilitating condition affecting many individuals with diabetes. NB-02 aims to alleviate the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases linked to tau protein malfunction. Gemcabene is being explored for an acute indication for COVID-19. Headquartered in Boston, Massachusetts, NeuroBo Pharmaceuticals operates with a small team focused on advancing its clinical programs and seeking strategic partnerships to expand its reach and impact.
What Products and Services Does NRBO Offer?
- Develop therapies for neurodegenerative diseases.
- Develop therapies for infectious diseases.
- Develop therapies for cardiometabolic diseases.
- Conduct clinical trials to evaluate the safety and efficacy of drug candidates.
- Seek regulatory approval for new therapies.
- Commercialize approved therapies.
- Explore strategic partnerships to expand their pipeline and market reach.
How Does NRBO Make Money?
- Develop proprietary drug candidates.
- Conduct clinical trials to demonstrate efficacy and safety.
- Seek regulatory approval from agencies like the FDA.
- Potentially partner with larger pharmaceutical companies for manufacturing and distribution.
What Industry Does NRBO Operate In?
NeuroBo Pharmaceuticals operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The industry is driven by innovation and the pursuit of novel treatments for unmet medical needs. NeuroBo's focus on neurodegenerative, infectious, and cardiometabolic diseases aligns with major healthcare challenges and market opportunities. The company faces competition from both large pharmaceutical companies and smaller biotech firms pursuing similar therapeutic targets. Success in this industry requires strong scientific expertise, effective clinical trial execution, and strategic partnerships.
Who Are NRBO's Key Customers?
- Patients suffering from neurodegenerative diseases.
- Patients suffering from infectious diseases like COVID-19.
- Patients suffering from cardiometabolic diseases like diabetic neuropathy.
- Healthcare providers who prescribe and administer these therapies.
Insider Activity
The most recent 12 insider filings for NeuroBo Pharmaceuticals, Inc. break down as 2 sales and 10 purchases. On net that is roughly 11.5M shares acquired (about $42.9M) — insiders putting money in tends to read as conviction.
NRBO Valuation & Market Position
With a $20.3M market cap, NeuroBo Pharmaceuticals, Inc. sits in the micro-cap segment of the market.
Key Financial Metrics
Return on assets is -91.2%, showing how much profit it generates from its asset base. A current ratio of 2.73 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -186.3%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
NeuroBo Pharmaceuticals, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -14.51 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project NeuroBo Pharmaceuticals, Inc. revenue of about $0 for fiscal 2026, with EPS near $-1.15.
Company Profile
NeuroBo Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO Hyung-Heon Kim. NRBO has traded publicly since 2016.
NRBO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- NRBO's recent insider buying suggests those in the know see long-term value, signaling potential confidence in the company's future prospects.
- The overall community sentiment seems cautiously optimistic, with many discussing the potential of their drug pipeline.
- Positive chatter around upcoming clinical trial results indicates anticipation of a positive catalyst.
- The market perception seems to be shifting, with increasing mentions in biotech forums and social media, suggesting growing awareness.
Bear Case
- Recent community discussions reveal concerns about the company's cash runway and potential need for future dilution.
- Some investors are wary, citing the inherent risks associated with biotech investments, especially those in early clinical stages.
- Negative sentiment has emerged regarding past trial outcomes from similar companies, creating a sense of caution.
- The market perception is still largely speculative, with limited institutional interest, suggesting a lack of validation from sophisticated investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NRBO Latest News
No recent news available for NRBO.
Leadership: Hyung-Heon Kim
CEO
Hyung-Heon Kim serves as the CEO of NeuroBo Pharmaceuticals, Inc. His background encompasses extensive experience in the biotechnology and pharmaceutical industries, with a focus on drug development and commercialization. He has held leadership positions at various companies, contributing to strategic planning, clinical trial management, and business development. His expertise spans multiple therapeutic areas, including neurodegenerative diseases, infectious diseases, and cardiometabolic disorders. He is responsible for managing 8 employees.
Track Record: Under Hyung-Heon Kim's leadership, NeuroBo Pharmaceuticals has focused on advancing its clinical pipeline, particularly ANA001 for COVID-19 and NB-01 for diabetic neuropathy. Key milestones include initiating and progressing clinical trials, securing funding to support research and development, and exploring strategic partnerships to expand the company's reach. He has overseen the company during a period of significant clinical development.
NeuroBo Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered
What happened to NeuroBo Pharmaceuticals, Inc. (NRBO) stock?
NeuroBo Pharmaceuticals, Inc. (NRBO) no longer trades on public markets. It was delisted in November 2024. The figures below are historical and are not a current quote.
Can I still buy NRBO shares?
No. NRBO stopped trading on public markets in November 2024, so the shares are not available through a broker. Anything you see quoted for NRBO elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before NRBO stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to NeuroBo Pharmaceuticals, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does NeuroBo Pharmaceuticals, Inc. do?
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing therapies for neurodegenerative, infectious, and cardiometabolic diseases. The company's pipeline includes ANA001, an oral niclosamide formulation in Phase 2/3 clinical trials for moderate COVID-19; NB-01 for painful diabetic neuropathy; NB-02 for cognitive impairment and neurodegenerative diseases; and Gemcabene for acute COVID-19. They aim to address unmet medical needs in these therapeutic areas through innovative drug development.
What do analysts say about NRBO stock?
Given NeuroBo Pharmaceuticals' market cap of $20.3M, analyst coverage may be limited. Any analyst reports would likely focus on the potential of its clinical pipeline, particularly ANA001 and NB-01. Key valuation metrics would include the probability of success for clinical trials, potential market size for approved therapies, and the company's cash runway. Investors should conduct their own due diligence and consider the inherent risks associated with clinical-stage biotechnology companies.
What are the main risks for NRBO?
NeuroBo Pharmaceuticals faces significant risks inherent to clinical-stage biotechnology companies. These include the risk of clinical trial failures, which could halt the development of key drug candidates. Regulatory setbacks or delays in obtaining approvals from agencies like the FDA could also impact the company's timeline and financial prospects. Competition from larger pharmaceutical companies with greater resources poses another challenge.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Investment decisions should be based on thorough research and consultation with a financial advisor.